Shilanski & Associates’s Moderna MRNA Stock Holding History

Shilanski & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,045	Closed	-$360K	–	167
2022 Q3	$360K	Buy	+3,045	New	+$462K	0.13%	86

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Shilanski & Associates's MRNA Position: Q4 2022 in Review

Shilanski & Associates sold out of Moderna (MRNA) in Q4 2022, closing a stake of 3,045 shares — an estimated $360K sold.

Shilanski & Associates first reported a position in MRNA in Q3 2022 and held it in 1 quarter. The position peaked at $360K in Q3 2022. 1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

Shilanski & Associates reported no remaining Moderna position as of Q4 2022 after selling out during the quarter.
Shilanski & Associates sold 3,045 Moderna shares in Q4 2022, an estimated $360K.
Shilanski & Associates first reported a position in Moderna in Q3 2022 and held it in 1 quarter.
Shilanski & Associates's Moderna position peaked at $360K in Q3 2022.
1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Shilanski & Associates's 13F filing for Q4 2022, filed 31 Jan 2023.